Deans' stroke musings: If You Know How to Cure Heart Disease, There's $75 Million Waiting

Changing stroke rehab and research worldwide now.Time is Brain! trillions and trillions of neurons that DIE each day because there are NO effective hyperacute therapies besides tPA(only 12% effective). I have 523 posts on hyperacute therapy, enough for researchers to spend decades proving them out. These are my personal ideas and blog on stroke rehabilitation and stroke research. Do not attempt any of these without checking with your medical provider. Unless you join me in agitating, when you need these therapies they won't be there.

What this blog is for:

My blog is not to help survivors recover, it is to have the 10 million yearly stroke survivors light fires underneath their doctors, stroke hospitals and stroke researchers to get stroke solved. 100% recovery. The stroke medical world is completely failing at that goal, they don't even have it as a goal. Shortly after getting out of the hospital and getting NO information on the process or protocols of stroke rehabilitation and recovery I started searching on the internet and found that no other survivor received useful information. This is an attempt to cover all stroke rehabilitation information that should be readily available to survivors so they can talk with informed knowledge to their medical staff. It lays out what needs to be done to get stroke survivors closer to 100% recovery. It's quite disgusting that this information is not available from every stroke association and doctors group.

Friday, January 15, 2016

If You Know How to Cure Heart Disease, There's $75 Million Waiting

Why haven't our fucking failures of stroke associations done this? They've had decades to come up with an idea like this.
http://www.medpagetoday.com/Cardiology/Prevention/55691?xid=nl_mpt_cardiodaily_2016-01-15&eun=gd3r
The project to cure coronary heart disease, now named One Brave Idea, opened for applications late Thursday as a collaboration among the American Heart Association, Verily (formerly Google Life Sciences), and now AstraZeneca.
The addition of the pharma company to the collaboration boosted the research grant for the winner to $75 million, bringing the total up from the initially-announced $50 million.
The team leader won't necessarily be a cardiovascular expert, Andy Conrad, CEO of Verily, noted when the project was first announced in November. "Could be a teenager from Wisconsin who has the best idea," he said.
Whoever is selected after the application period ends Feb. 14 will also get technical resources from Verily, scientific and mentoring help from AstraZeneca, and guidance from two or three leaders from each of the three funding organizations.
The interdisciplinary approach is key, AHA CEO Nancy Brown said in a press release from her group.
"We are trying to do something disruptive here," she said. "This is our moonshot -- it's an unprecedented opportunity for the world's best and brightest to address a leading health threat. It all starts with the search for a leader and a vision to end coronary heart disease."
The funding institutions stand to benefit financially from any patents that arise, but the AHA, which is responsible for administering the research program, has a policy largely aimed at getting the research into public use as soon as possible.
That, too, was the idea behind the short, 1-month formal application period, according to Amit Chitre, AHA executive vice president for corporate communications.
"One Brave Idea is fundamentally a different kind of model in many respects, including its application process and research funding, which was designed to remove the barriers and the silos that plague traditional research projects, like lengthy and time consuming application processes," he told MedPage Today via email.